Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy

BACKGROUND: Pazopanib achieved the end point of clinical activity in pretreated patients with urothelial cancer in a single-group, phase 2 trial. The objective was to identify biological predictors of clinical benefit to pazopanib in these patients. METHODS: EDTA blood samples were collected at base...

Descripción completa

Detalles Bibliográficos
Autores principales: Necchi, A, Pennati, M, Zaffaroni, N, Landoni, E, Giannatempo, P, Raggi, D, Schwartz, L H, Morosi, C, Crippa, F, Farè, E, Nicolai, N, Lanocita, R, Sava, T, Sacco, C, Messina, C, Ortega, C, De Braud, F G, Salvioni, R, Daidone, M G, Gianni, A M, Mariani, L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887307/
https://www.ncbi.nlm.nih.gov/pubmed/24231947
http://dx.doi.org/10.1038/bjc.2013.719

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887307/
https://www.ncbi.nlm.nih.gov/pubmed/24231947
http://dx.doi.org/10.1038/bjc.2013.719

Ejemplares similares